TRANS GENIC GROUP INC. Logo

TRANS GENIC GROUP INC.

Biotech firm offering drug discovery support and investment/consulting services.

2342 | T

Overview

Corporate Details

ISIN(s):
JP3635720000
LEI:
Country:
Japan
Address:
福岡市中央区天神二丁目3番36号

Description

TRANS GENIC GROUP INC. is a biotechnology company that operates through two main business segments: Drug Discovery Support and Investment & Consulting. The Drug Discovery Support division provides comprehensive services across the entire drug development pipeline, from basic research to non-clinical and clinical trials. Core services include the contract production of genetically modified animals, particularly mice, using genome editing technologies like CRISPR/Cas9. The company also specializes in contract antibody production, glycosylation analysis, and the supply of model mice. The Investment & Consulting segment focuses on M&A, business succession, and providing advisory and support services for business revitalization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 02:36
確認書
Japanese 8.2 KB
2025-11-13 02:33
半期報告書-第28期(2025/04/01-2026/03/31)
Japanese 189.2 KB
2025-08-01 09:45
訂正確認書
Japanese 8.2 KB
2025-08-01 09:44
訂正有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 667.3 KB
2025-07-02 05:53
訂正臨時報告書
Japanese 24.4 KB
2025-07-01 10:02
臨時報告書
Japanese 24.4 KB
2025-06-30 09:38
確認書
Japanese 8.6 KB
2025-06-30 09:37
内部統制報告書-第27期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-06-30 09:34
有価証券報告書-第27期(2024/04/01-2025/03/31)
Japanese 1.1 MB
2025-06-13 10:13
臨時報告書
Japanese 21.2 KB
2025-04-23 09:55
臨時報告書
Japanese 20.1 KB
2024-11-13 02:42
確認書
Japanese 8.5 KB
2024-11-13 02:41
半期報告書-第27期(2024/04/01-2025/03/31)
Japanese 191.9 KB
2024-06-24 08:30
臨時報告書
Japanese 19.8 KB
2024-06-21 07:03
有価証券報告書-第26期(2023/04/01-2024/03/31)
Japanese 1.0 MB

Automate Your Workflow. Get a real-time feed of all TRANS GENIC GROUP INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TRANS GENIC GROUP INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TRANS GENIC GROUP INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.